A novel potential therapy for vascular diseases: blood‐derived stem/progenitor cells specifically activated by dendritic cells

Porat, Yael; Assa-Kunik, Efrat; Belkin, Michael; Krakovsky, Michael; Lamensdorf, Itschak; Duvdevani, Revital; Sivak, Galit; Niven, Mark; Bulvik, Shlomo

doi:10.1002/dmrr.2543

Cited by 11 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stem cell treatments with BM-derived cells (BMDCs) show safety outcomes but also adverse events related to cell collection and mobilization. Porat et al postulated that alternatively activated dendritic cells (DCs) can promote the generation of EPC-enriched stem cells within a one-day culture [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

Cell Therapy in Patients with Critical Limb Ischemia

Compagna

Amato

Massa

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

Critical limb ischemia (CLI) represents the most advanced stage of peripheral arterial obstructive disease (PAOD) with a severe obstruction of the arteries which markedly reduces blood flow to the extremities and has progressed to the point of severe rest pain and/or even tissue loss. Recent therapeutic strategies have focused on restoring this balance in favor of tissue survival using exogenous molecular and cellular agents to promote regeneration of the vasculature. These are based on stimulation of angiogenesis by extracellular and cellular components. This review article carries out a systematic analysis of the most recent scientific literature on the application of stem cells in patients with CLI. The results obtained from the detailed analysis of the recent literature data have confirmed the beneficial role of cell therapy in reducing the rate of major amputations in patients with CLI and improving their quality of life.

show abstract

Section: Resultsmentioning

confidence: 99%

Cell Therapy in Patients with Critical Limb Ischemia

Compagna

Amato

Massa

et al. 2015

Stem Cells International

View full text Add to dashboard Cite

show abstract

“…However, difficulty was seen in connection to the collection and mobilization of cells. A one-day culture of activated dendritic cells (DC) allowed us to observe the development of EPC-enriched stem cells [29].…”

Section: Stromal Cell Mobilizationmentioning

confidence: 99%

Stem Cell Therapy in Critical Limb Ischemia

Jeyaraman,

Nagarajan,

Maffulli

et al. 2023

Cureus

View full text Add to dashboard Cite

Critical limb ischemia (CLI), a serious outcome of peripheral artery disease, is frequently associated with morbid outcomes. The available treatment modalities do not provide satisfactory results, leading to marked morbidities such as joint contracture and amputations, resulting in a high economic burden. The peripheral vascular disease tends to cause more morbidity in patients with diabetes and atherosclerosis, given the preexisting compromised perfusion of medium and small vessels in diabetic patients. With surgical procedures, the chance of vascular compromise further increases, inducing a significantly greater rate of amputation. Hence, the need for nonsurgical treatment modalities such as stem cell therapy (SCT), which promotes angiogenesis, is warranted. In CLI, SCT acts through neovascularization and the development of collateral arteries, which increases blood supply to the soft tissues of the ischemic limb, providing satisfactory outcomes. An electronic database search was performed in PubMed, SCOPUS, EMBASE, and ScienceDirect to identify published clinical trial data, research studies, and review articles on stem cell therapy in critical limb ischemia. The search resulted in a total of 2391 results. Duplicate articles screening resulted in 565 articles. In-depth screening of abstracts and research titles excluded 520 articles, yielding 45 articles suitable for full-text review. On review of full text, articles with overlapping and similar results were filtered, ending in 25 articles.SCT promotes arteriogenesis, and bone marrow-derived mesenchymal stromal cells produce significant effects like reduced morbidity, improved amputation-free survival (AFS ) rate, and improved distal perfusion even in "no-option" CLI patients. SCT is a promising treatment modality for CLI patients, even in those in whom endovascular and revascularization procedures are impossible. SCT assures a prolonged AFS rate, improved distal perfusion, improved walking distances, reduced amputation rates, and increased survival ratio, and is well-tolerated.

show abstract

“…In this issue of Diabetes Metabolism Research and Reviews, Porat et al report a method to treat vascular disease in diabetic patients with blood-derived stem or progenitor cells [15]. Using blood bank-donated samples from nondiabetic subjects, dendritic cells and stem/progenitor cells were enriched by antibody selection for cell surface markers.…”

mentioning

confidence: 99%